

ASX Code: GSS

19 November 2019

Successful Completion of Share Purchase Plan

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”), an Australian leader in molecular diagnostics, advises the Share Purchase Plan (SPP) announced on Monday 28 October 2019, closed on Friday 15 November 2019 oversubscribed.

The SPP was strongly supported by eligible shareholders and applications received exceeded the \$2 million sought under the Offer by more than 50%. Genetic Signatures has exercised its discretion under the terms & conditions of the SPP to increase the aggregate amount accepted to \$2.5 million, then to scale back the allotment in excess of this amount on a pro rata basis.

The new shares will be issued at 0.98 cents per share, being the same price paid by institutional investors under the Share Placement announced Monday 28 October 2019, which was also oversubscribed.

Genetic Signatures Chief Executive Officer John Melki said:

“We are very pleased with the positive response shown by our shareholders and their ongoing support for the company. In addition to the institutional placement, proceeds raised under the SPP will help expand our sales and marketing teams and rapidly grow global revenues and meet demand for our innovative products. The business is now well positioned take full advantage of pending regulatory and commercial milestones in the major markets of Europe and the US.”

Genetic Signatures expects the SPP shares to be issued on Monday 25 November 2019 and to commence trade on the Australian Securities Exchange (ASX) on Tuesday 26 November 2019.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**[™]. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*[™] brand. Genetic Signatures’ proprietary MDx **3base**[™] platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.